Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

HealthDay News — Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July 15 in the ...

The first recall affects tuna salad and ready-to-eat foods containing tuna salad from Beaverton, Oregon-based Reser's Fine Foods.

HealthDay News — More than 100,000 Rich’s Ice Cream Co. bars have been recalled due to possible listeria contamination. The affected ice cream bars were sold across 23 states and in Nassau, capital of ...

and 50.4 percent of those with one and two or more moderate risk factors were recommended aspirin prophylaxis.

HealthDay News — The US Food and Drug Administration has appointed George Francis Tidmarsh, MD, PhD, as director of the Center for Drug Evaluation and Research (CDER).

The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

HealthDay News — The US Department of Health and Human Services has announced a major initiative to reform the organ transplant system. This action follows an investigation by the Health Resources and ...

Six or 9 months of bedaquiline, delamanid, linezolid, and clofazimine was not noninferior to longer standard of care.